GlobalData on MSN13h
Eli Lilly reports outcomes from Phase III trial of tirzepatide for HFpEFThe trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.
The Company is seeking approval of tirzepatide for the treatment of HFpEF and obesity and has submitted data to the FDA. Detailed results were announced from a phase 3 clinical trial evaluating the ...
In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking ...
SUMMT has shown for the first time that a drug can reduce major heart failure clinical outcomes in patients with heart ...
"Obesity contributes to worsening heart failure, and while tirzepatide causes considerable weight loss, research is lacking ...
Spanning 176 weeks of treatment, the Phase III trial evaluated the efficacy and safety of tirzepatide in adults without type ...
HF specialists agree these drugs will be key tools in fighting the obesity-related HFpEF epidemic. Hurdles and questions ...
Medpage Today on MSN2d
Tirzepatide Officially Puts GLP-1 Meds on the Map for Obesity-Related Heart FailureCHICAGO -- A long-acting GIP/GLP-1 receptor agonist conferred significant clinical benefit for people with obesity and ...
Real-world data on GLP-1R agonists’ safety in heart failure and CKD patients was investigated using the TriNetX Research ...
The detailed results were published in The New England Journal of Medicine and were presented at ObesityWeek 2024.
The results from the SUMMIT trial of tirzepatide in obese patients with heart failure ... a nearly 25-point improvement in ...
Obesity is a chronic condition and a key risk factor for a range of other health issues, including type 2 diabetes. In a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback